Optimizing Glycemic Control with Metformin and DPP-4 Inhibitors

Introduction to Combination Therapy

The American Diabetes Association recommends metformin as the preferred and most cost-effective first-line agent for glycemic control, unless contraindicated, and it should continue as the backbone of therapy even when adding additional agents 1, 2
Metformin reduces A1C approximately 0.43% more than DPP-4 inhibitors, making DPP-4 inhibitors the weaker glucose-lowering agent 3

The American College of Endocrinology suggests increasing metformin to 1000mg twice daily (maximum dose) before adding combination therapy, and titrating gradually to minimize gastrointestinal side effects 1, 2
Reassess A1C in 3 months after metformin optimization 1
If A1C remains ≥7% after metformin optimization, add a DPP-4 inhibitor (like sitagliptin/Synjardi) to metformin as combination therapy, as recommended by the American Association of Clinical Endocrinologists 1, 2

Prioritize SGLT-2 inhibitors or GLP-1 receptor agonists over DPP-4 inhibitors for patients with cardiovascular disease, heart failure, or chronic kidney disease, due to proven cardiovascular and renal benefits, as suggested by the American Heart Association 1
Metformin can be safely used with eGFR ≥30 mL/min/1.73 m², but requires monitoring, according to the National Kidney Foundation 1
For eGFR 30-45 mL/min/1.73 m², there is increased risk of lactic acidosis requiring closer monitoring 1

Increase metformin to 1000mg twice daily (if tolerated and no contraindications) at the next visit, as recommended by the American Diabetes Association 1
Provide gradual titration schedule to minimize GI side effects, and schedule follow-up in 3 months to reassess A1C 1, 2